Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells

Journal of Investigative Dermatology

Volumn 135, Issue 3, 2015, Pages 842-850

  Mukherjee, Nabanita ^a   Reuland, Steven N ^a   Lu, Yan ^a   Luo, Yuchun ^a   Lambert, Karoline ^a   Fujita, Mayumi ^a   Robinson, William A ^a   Robinson, Steven E ^a   Norris, David A ^a,b   Shellman, Yiqun G ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALDEHYDE DEHYDROGENASE; BIM PROTEIN; FENRETINIDE; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; ABT-737; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; NITROPHENOL; PIPERAZINE DERIVATIVE; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL 2; RETINOID; SULFONAMIDE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CELL DEATH; CELL DENSITY; CELL KILLING; CELL POPULATION; CELL SUSPENSION; CELL VIABILITY; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MELANOMA INITIATING CELL; MOUSE; MTS ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL SURVIVAL; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FENRETINIDE; HUMANS; MELANOMA; NEOPLASTIC STEM CELLS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOIDS; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84922604221     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.464     Document Type: Article

References (42)

1. Arbiser JL, Bips M, Seidler A et al. (2012) Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases. J Am Acad Dermatol 67:e81-3
2. Beck B, Blanpain C (2013) Unravelling cancer stem cell potential. Nat Rev Cancer 13:727-38
3. Bruno S, Ghiotto F, Tenca C et al. (2012) N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity. Leukemia 26:2260-8
4. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med 364:2507-16
5. Civenni G, Walter A, Kobert N et al. (2011) Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-Term growth. Cancer Res 71:3098-109
6. Czabotar PE, Lessene G, Strasser A et al. (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15:49-63
7. Dontu G, Abdallah WM, Foley JM et al. (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253-70
8. Eberle J, Hossini AM (2008) Expression and function of bcl-2 proteins in melanoma. Curr Genomics 9:409-19
9. Fang D, Nguyen TK, Leishear K et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-37
10. Fang H, Harned TM, Kalous O et al. (2011) Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clin Cancer Res 17:7093-104
11. Finn L, Markovic SN, Joseph RW (2012) Therapy for metastatic melanoma: the past, present, and future. BMC Med 10:23
12. Garbe C, Eigentler TK, Keilholz U et al. (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5-24
13. Haass NK, Schumacher U (2014) Melanoma never says die. Exp Dermatol 23:471-2
14. Iwanaga R, Wang CA, Micalizzi DS et al. (2012) Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res 14:R100
15. Kang MH, Wan Z, Kang YH et al. (2008) Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100:580-95
16. Lee N, Barthel SR, Schatton T (2014) Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest 94:13-30
17. Lucas KM, Mohana-Kumaran N, Lau D et al. (2012) Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res 18:783-95
18. Luo Y, Dallaglio K, Chen Y et al. (2012) ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30:2100-13
19. Malone W, Perloff M, Crowell J et al. (2003) Fenretinide: a prototype cancer prevention drug. Expert Opin Invest Drugs 12:1829-42
20. Maurer BJ, Melton L, Billups C et al. (2000) Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92:1897-909
21. Miller LA, Goldstein NB, Johannes WU et al. (2009) BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxadependent apoptosis. J Invest Dermatol 129:964-71
22. Mohana-Kumaran N, Hill DS, Allen JD et al. (2014) Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell Melanoma Res 27:525-39
23. Monzani E, Facchetti F, Galmozzi E et al. (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935-46
24. Oltersdorf T, Elmore SW, Shoemaker AR et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-81
25. Placzek WJ, Wei J, Kitada S et al. (2010) A survey of the anti-Apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 1:e40
26. Ramirez-Labrada A, Lopez-Royuela N, Jarauta V et al. (2014) Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. Clin Transl Oncol; e-pub ahead of print 19 July 2014
27. Reginato MJ, Mills KR, Paulus JK et al. (2003) Integrins and EGFR coordinately regulate the pro-Apoptotic protein Bim to prevent anoikis. Nat Cell Biol 5:733-40
28. Reuland SN, Goldstein NB, Partyka KA et al. (2011) The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53. PLoS One 6:e24294
29. Reuland SN, Goldstein NB, Partyka KA et al. (2012) ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open 1:92-100
30. Ribble D, Goldstein NB, Norris DA et al. (2005) A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 5:12
31. Roesch A, Fukunaga-Kalabis M, Schmidt EC et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141:583-94
32. Roesch A, Vultur A, Bogeski I et al. (2013) Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23:811-25
33. Santini R, Vinci MC, Pandolfi S et al. (2012) Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. Stem Cells 30:1808-18
34. Shakhova O, Sommer L (2013) Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. Cancer Lett 338:74-81
35. Smith SM, Ribble D, Goldstein NB et al. (2012) A simple technique for quantifying apoptosis in 96-well plates. In: PMC (eds) Laboratory Methods in Cell Biology. 1st edn. Elsevier Inc.: Chennai, India, 361-8
36. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138-51
37. Stecca B, Santini R, Pandolfi S et al. (2013) Culture and isolation of melanomainitiating cells. Curr Protoc Stem Cell Biol Chapter 3:Unit 3 6
38. Tentler JJ, Tan AC, Weekes CD et al. (2012) Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9:338-50
39. Thomas S, Quinn BA, Das SK et al. (2013) Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 17:61-75
40. Torrisi R, Decensi A (2000) Fenretinide and cancer prevention. Curr Oncol Rep 2:263-70
41. Wong CY, Helm MA, Kalb RE et al. (2013) The presentation, pathology, and current management strategies of cutaneous metastasis. N Am J Med Sci 5:499-504
42. Zhang H, Mi JQ, Fang H et al. (2013) Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci USA 110:5606-11